Jeff Jones, Managing Director, Senior Analyst at Oppenheimer & Company

On our first episode of ‘Talk Radioisotopes: Going Nuclear on Cancer,' host Scott Larrivee is joined by co-host Dr. Sarah Scouten and guest Jeff Jones of Oppenheimer & Company.The discussion covers the latest trends in the radiopharmaceutical and radiotherapeutics markets, including the rise of targeted radiotherapies, the involvement of large pharmaceutical companies, and key developments in isotope supply chains. Jeff provides insights from Oppenheimer's recent summit on radiotherapy, covering emerging technologies, new isotopes, and the regulatory and logistical challenges ahead. Sarah discusses the broader implications for the oncology field and the importance of clinician and infrastructure readiness. The episode concludes with a look ahead to 2025, discussing potential advancements, technological innovations, and how the political landscape might impact the future of cancer treatments.—-----Time Stamps:*(01:55) Jeff's 20 Year Career in Biotech*(07:12) The Infamous Oppenheimer Chart*(09:59) 9 Billion in Acquisitions*(16:58) Finding the right isotope for each patient*(19:19) Up-and-coming Isotopes*(23:18) How Prepared is the Industry?*(29:27) The Regulatory Environment of Radiotherapeutics*(33:53) The Next 5 Years of Radiopharmaceuticals--------‘Talk Radioisotopes: Going Nuclear on Cancer’ is brought to you by Nusano, a physics company whose breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. Find out more at Nusano.com.--------Links:Follow Jeff on LinkedInVisit Oppenheimer.comTalkradioisotopes.com-------